Table 1.
Assessment of plasma- and cell-associated viremia in Fozivudine tidoxil (FZD) and placebo-treated cats during chronic Feline Immunodeficiency virus (FIV) infection. The percentage of positive cats by PCR analysis is shown in the first row for FZD- and placebo-treated groups and the corresponding number of cats out of each group is displayed on the second row. The mean, median, and range of the plasma viremia in number of virus copies/mL are listed for each treatment group at 1, 2, and 3 years PI. The mean, median and range of the cell-associated viremia in copies/106 Peripheral blood mononuclear cells (PBMCs) are listed for each treatment group at 3 years PI. Five cats were evaluated for each experimental group. (p < 0.05, NS = not significant).
| FIV-gag-mRNA | ||||
|---|---|---|---|---|
| [copies/mL plasma] | [copies/106 PBMCs] | |||
| Years Post infection | 1 | 2 | 3 | 3 |
| FZD | ||||
| Positive (%) | 100 | 100 | 100 | 40 |
| (5/5) | (5/5) | (5/5) | (2/5) | |
| Mean | 2.91 | 4.84 | 2.74 | 1.44 |
| Median | 2.80 | 4.26 | 2.77 | 1.44 |
| Range | 2.27–3.67 | 3.87–6.76 | 2.04–3.85 | 1.41–1.46 |
| Placebo | ||||
| Positive (%) | 100 | 100 | 100 | 60 |
| (5/5) | (5/5) | (5/5) | (3/5) | |
| Mean | 3.40 | 4.81 | 2.59 | 1.39 |
| Median | 3.32 | 4.27 | 2.33 | 1.46 |
| Range | 2.96–3.98 | 3.89–6.81 | 1.93–3.97 | 1.16–1.54 |
| p-value | NS | NS | NS | NS |